In t-MDS patients, it was significantly poorer for TP53-mutant compared to TP53-WT patients; among t-MDS, particularly TP53-mutant patients, mOS does not seem to be affected by TP53 VAF or TP53 multi-hit or mono-hit status [86]. This evidence concerns the gene TP53 and myelodysplastic syndrome.